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Racial Differences in the Effect of Granulocyte Macrophage
Colony-Stimulating Factor on Improved Walking Distance in
Peripheral Artery Disease: The PROPEL Randomized Clinical Trial
Mary M. McDermott, MD; Tamar S. Polonsky, MD; Jack M. Guralnik, MD, PhD; Luigi Ferrucci, MD, PhD; Lu Tian, ScD; Lihui Zhao, PhD;
James Stein, MD; Kathryn Domanchuk, BS; Michael H. Criqui, MD, MPH; Doris A. Taylor, PhD; Lingyu Li, MS; Melina R. Kibbe, MD
Background-—The effects of race on response to medical therapy in people with peripheral artery disease (PAD) are unknown.
Methods and Results-—In the PROPEL (Progenitor Cell Release Plus Exercise to Improve Functional Performance in PAD) Trial, PAD
participants were randomized to 1 of 4 groups for 6 months: supervised treadmill exercise+granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Group 1), exercise+placebo (Group 2), attention control+GM-CSF (Group 3), or attention
control+placebo (Group 4). Change in 6-minute walk distance was measured at 12- and 26-week follow-up. In these exploratory
analyses, groups receiving GM-CSF (Groups 1 and 3), placebo (Groups 2 and 4), exercise (Groups 1 and 2), and attention control
(Groups 2 and 4) were combined, maximizing statistical power for studying the effects of race on response to interventions. Of 210
PAD participants, 141 (67%) were black and 64 (30%) were white. Among whites, GM-CSF improved 6-minute walk distance by
+22.0 m (95% CI: 4.5, +48.5, P=0.103) at 12 weeks and +44.4 m (95% CI: +6.9, +82.0, P=0.020) at 26 weeks, compared with
placebo. Among black participants, there was no effect of GM-CSF on 6-minute walk distance at 12-week (P=0.26) or 26-week
(5.0 m [27.5, +17.5, P=0.66]) follow-up, compared with placebo. There was an interaction of race on the effect of GM-CSF on
6-minute walk change at 26-week follow-up (P=0.018). Exercise improved 6-minute walk distance in black (P=0.006) and white
(P=0.034) participants without interaction.
Conclusions-—GM-CSF improved 6-minute walk distance in whites with PAD but had no effect in black participants. Further study
is needed to confirm racial differences in GM-CSF efficacy in PAD.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01408901. ( J Am Heart Assoc. 2019;8:
e011001. DOI: 10.1161/JAHA.118.011001.)
Key Words: exercise training • peripheral artery disease • peripheral vasculature • stem cell
B lack patients with lower extremity peripheral arterydisease (PAD) present with more severe lower extremity
atherosclerosis, have greater functional impairment, and have
higher rates of mobility loss, compared with whites with
PAD.1–3 Black patients with PAD have higher rates of critical
limb ischemia and amputation compared with nonblack
people with PAD.4–9 Despite these racial differences in
disease severity and lower extremity outcomes, whether race
affects responsiveness to medical therapy in people with PAD
is unknown.
Colony-stimulating factors, such as granulocyte-macro-
phage colony-stimulating factor (GM-CSF), mobilize progenitor
cells from bone marrow and spleen into the peripheral
circulation and may improve walking performance in people
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with PAD by promoting angiogenesis and improving endothe-
lial function and cardiovascular health.10–15 The PROPEL
(Progenitor Cell Release Plus Exercise to Improve Functional
Performance in PAD) randomized clinical trial studied whether
GM-CSF with and without supervised treadmill exercise
significantly improved 6-minute walk distance in people with
PAD.16 In post hoc exploratory analyses, the effects of race on
the efficacy of GM-CSF and exercise in people with PAD were
studied, to determine whether GM-CSF and exercise had
differential effects on change in 6-minute walk distance in
black participants with PAD compared with white participants
with PAD.
Methods
The Institutional Review Board at Northwestern University and
all recruitment sites approved the protocol. Participants
provided written, informed consent. The data supporting the
findings of this study are available from the corresponding
author upon reasonable request, within constraints allowed by
the institutional review board.
Participants were randomized between January 6, 2012
and December 22, 2016. The final follow-up visit was on
August 15, 2017. The clinical trial used a 292 factorial
design, and participants with PAD were randomized to 1 of 4
groups: supervised treadmill exercise+GM-CSF (Group 1),
supervised treadmill exercise+placebo (Group 2), attention
control+GM-CSF (Group 3), or attention control+placebo
(Group 4). Methods and primary results have been
reported.15,16 In post hoc analyses, the effect of GM-CSF
and exercise, respectively, on the primary outcome was
evaluated by black versus white race. In these analyses, the 2
groups receiving GM-CSF (Groups 1 and 3), placebo (Groups 2
and 4), exercise (Groups 1 and 2), and attention control
(Groups 3 and 4) were combined, to maximize sample sizes
when evaluating the effect of GM-CSF and exercise on change
in 6-minute walk distance among blacks and whites,
respectively.
Participant Identification
Participants were identified from multiple Chicago-area
medical centers, through newspaper or radio advertise-
ments, and from postcard mailings to people age 55 years
and older in the Chicago area. People with PAD who
previously participated in research with the principal
investigator (M.M.M.) and expressed interest in future
research were contacted.
Inclusion Criteria
Inclusion criteria included an ankle-brachial index (ABI)
≤0.90.17 Potential participants with an ABI >0.90 at baseline
were eligible if there was hospital-affiliated vascular labora-
tory evidence of PAD. Participants with an ABI of >0.90 or
≤1.00 at the baseline study visit and those with a normal ABI
and prior lower extremity revascularization were eligible if
they had a 20% drop in ABI following a heel-rise test.17,18
Exclusion Criteria
Potential participants with a below- or above-knee amputa-
tion, wheelchair confinement, who used a walking aid other
than a cane, who were unable or unwilling to attend exercise
sessions 3 times per week, whose walking impairment was
because of a reason other than PAD, or who had a foot ulcer,
critical limb ischemia, or significant visual or hearing impair-
ment were excluded. Potential participants who did not
complete the study run-in were excluded. The run-in consisted
of attending 1 weekly health education session and 1
treadmill exercise session within a 3-week period. Potential
participants with major surgery or revascularization during the
previous 3 months or planned during the next 6 months,
participation in another clinical trial or cardiac rehabilitation
within the past 3 months, Parkinson’s disease, and those
requiring oxygen with activity were excluded. Potential
participants for whom exercise may be unsafe, including
those with >Class II New York Heart Association heart failure
or angina, an increase in angina pectoris during the prior
6 months, or an abnormal baseline stress test were excluded.
Participants already exercising at a level similar to that in the
intervention were excluded. Participants recently treated for
cancer were excluded unless their cancer was early-stage and
their cancer prognosis was excellent. Potential participants
Clinical Perspective
What Is New?
• Among people with lower extremity peripheral artery disease
(PAD) participating in a randomized clinical trial comparing
granulocyte-macrophage colony-stimulating factor versus pla-
cebo, granulocyte-macrophage colony-stimulating factor
improved 6-minute walk distance in white participants with
PAD but not in black participants with PAD.
• In contrast to findings for granulocyte-macrophage colony-
stimulating factor, supervised treadmill exercise improved 6-
minute walk distance in both white and black participants
with PAD.
• GM-CSF had a significantly greater beneficial effect in white
participants with PAD compared to black participants with PAD.
What Are the Clinical Implications?
• Granulocyte-macrophage colony-stimulating factor may
improve walking distance in white people with PAD but
not in black people with PAD.
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with a Mini-Mental Status Examination score <23 were
excluded.19
Race
Race was measured by asking participants how they classified
their race, in an open-ended manner. Only participants who
described their race as “black” or “white” were included in
these analyses.
Randomization
Participants were randomized to 1 of 4 groups using a SAS
computer program: GM-CSF+supervised exercise, GM-
CSF+attention control, placebo+supervised exercise, or
placebo+attention control. Randomization was stratified by
diabetes mellitus.20 Block randomization was used, with block
sizes randomly selected from 8 and 12.
Interventions
GM-CSF and placebo
GM-CSF (250 lg/m2 per day) or placebo was administered
subcutaneously at the medical center 3 times weekly during the
first 2 weeks after randomization, in a double-blinded fashion.
Supervised treadmill exercise and attention control
Supervised treadmill exercise was provided 3 times weekly,
beginning at 15 minutes per session and increasing exercise
by 5 minutes per session each week until up to 50 minutes of
exercise per session was achieved. Participants randomized
to the attention control group attended weekly 1-hour
educational sessions on health topics of interest to PAD
patients, including cancer screening, immunizations, nutri-
tional supplements, and hypertension.
Outcomes
Outcome data were collected by individuals blinded to group
assignment. The prespecified primary outcome was change in
6-minute walk distance between baseline and 12-week follow-
up. Brachial artery flow-mediated dilation (FMD) was a
secondary outcome. Endothelial progenitor cells were an
exploratory outcome. To assess temporal changes, outcomes
were also measured at 6- and at 26-week follow-up.
Six-Minute Walk Test
The 6-minute walk is a well-validated measure of walking
endurance for people with PAD.21–25 Following a standardized
protocol,21–25 participants walked up and down a 100-foot
hallway for 6 minutes after instructions to cover as much
distance as possible. The distance completed after 6 minutes
was recorded. A small clinically meaningful change was
defined as 20 m and a large meaningful change as 50 m.25
Brachial Artery FMD
FMD of the proximal brachial artery was performed using B-
mode and Doppler ultrasound with a linear array vascular
ultrasound transducer.15,16,22 Doppler blood flow in the
brachial artery was recorded at rest and immediately after
hyperemia induction. Brachial artery diameters were recorded
at rest and then 60 and 90 s after cuff deflation. FMD was
defined as the ratio of the maximum brachial artery diameter
after reactive hyperemia to the resting diameter, expressed as
a percent. Images were interpreted by a single reader
unaware of group assignment.15,16,22
Progenitor Cells
Progenitor cells were measured at baseline and 2-week
follow-up. Peripheral blood from a peripheral venipuncture
was washed in lysis buffer to lyse red blood cells. Remaining
cell counts were obtained using the Countess Automated Cell
Counter (Life Technologies, NY) as previously described.15,26
Additional Measures
Ankle-brachial index
A handheld Doppler probe (Nicolet Vascular Pocket Dop II,
Golden, CO) was used to measure systolic blood pressures
after the participant rested supine for 5 minutes. Pressures
were measured in the following order: right brachial, dorsalis
pedis, and posterior tibial arteries and left dorsalis pedis,
posterior tibial, and brachial arteries. Pressures were repeated
in reverse order. The ABI was calculated by dividing average
pressures in each leg by the average of the 4 brachial
pressures.15–17,27,28 Heel-rise testing, when indicated for
eligibility, consisted of 50 heel rises at a rate of 1 per s
followed by repeat ABI measurement.18
Other measures
Medical history and demographics were obtained using
patient report.15,16 Body mass index (BMI) was calculated
as weight (kg) divided by (height [meters])2.
Leg symptoms
Leg symptoms were characterized using the San Diego
Claudication Questionnaire.29,30 Intermittent claudication was
defined as exertional calf pain that did not begin at rest,
caused the participant to stop walking, and resolved within
10 minutes of rest. Participants without intermittent claudi-
cation were classified as either asymptomatic (ie, reported no
exertional leg symptoms) or with exertional leg symptoms
that did not meet criteria for intermittent claudication.29,30
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Power Calculations
Results reported here are exploratory results for the PROPEL
Trial16 and therefore no power calculations were performed.
For the overall trial, a target sample size of 240 participants
was calculated to achieve the primary aim and recruitment
ended when recruitment resources were exhausted.
Statistical Analysis
Baseline characteristics were compared between blacks and
white participants using v2 testing for categorical variables
and t testing for continuous variables. Among blacks and
whites, characteristics of those randomized to GM-CSF and
those randomized to placebo were compared using v2 tests
*Data were imputed for parcipants who were lost to follow-up or who canceled the visit.
Assessed for eligibility (n=827)
Randomized (n=210)
Excluded (n=617)
-No peripheral artery disease- not eligible 
(n=439)
-Not interested or not able to attend three 
sessions per week (n=89)
-Walking not primarily limited by peripheral 
artery disease (n=24)
-Already walking for exercise three times weekly 
(n=15)
-Did not complete run in (n=15)
-Participant poorly suited (n=12)
-Unstable angina, abnormal coronary exercise 
stress test or aortic stenosis (n=11)
-Major medical illness or treatment for cancer in 
last three years (n=4)
-Planned revascularization or recent major 
surgery or revascularization (n=4)
-Low mini-mental status examination or severe 
psychiatric (n=2)
-Critical limb ischemia (n=1)
-Current clinical trial participation (n=1)Allocation
Allocated to GM-CSF + 
supervised exercise 
intervention (n=53) 
-Did not attend exercise 
sessions (lost interest) 
(n=1)
-Did not receive injection 
and did not attend 
exercise sessions (lost 
interest) (n=1)
Allocated to GM-CSF + 
attention control (n=51) 
- Did not receive 
injection (lost interest) 
(n=2)
-Did not receive attention 
control (lost interest) 
(n=1)
-Did not receive injection 
and did not attend health 
education sessions (lost 
interest) (n=1)
Allocated to placebo + 
supervised exercise 
intervention (n=52) 
- Did not receive injection 
(lost interest) (n=2)
-Did not receive injection 
and did not attend exercise 
sessions (lost interest) 
(n=2)
Allocated to placebo + 
attention control (n=49) 
-Did not attend health 
education sessions (lost 
interest) (n=2)
-Did not receive injection 
and did not attend health 
education sessions (lost 
interest) (n=2)
6-Week Follow-Up
Lost to follow-up (n=2)
Death (n=1)
Discontinued injection 
(side effects) (n=6)
Discontinued exercise 
sessions (lost interest)   
(n=1)
Analyzed (n=52)*
Excluded from analysis 
(death) (n=1)
Lost to follow-up (n=1)
Canceled visit (n=1)
Discontinued injection 
(side effects) (n=6)
Analyzed (n=51)*
Lost to follow-up (n=3)
Analyzed (n=52)*
Lost to follow-up (n=2)
Discontinued injection 
(lost interest) (n=2)
Canceled visit (n=2)
Analyzed (n=49)*
Excluded from analyses due to not 
Black or White race (n=5)
Figure 1. Consort diagram of randomization and follow-up rates by group.
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for categorical variables and t tests for continuous variables.
Statistical analyses were performed according to intention to
treat. A statistical test for interaction between GM-CSF and
exercise was performed, to ensure that it was appropriate to
examine the effect of exercise and GM-CSF, separately, in
blacks and white participants. Changes in 6-minute walk
distance between baseline and 12-week follow-up were
compared between groups using a 2-sample t test. Analyses
were repeated for changes in 6-minute walk distance at 6-
week and at 26-week follow-up. For missing data, multiple
imputation was used by using PROC MI, obtaining 20 imputed
data sets. Imputation was performed by treatment group.
Variables included in the imputation were age, ABI, BMI, sex,
smoking status, baseline outcome measures, leg symptoms,
and comorbidities. Imputed results were combined using
PROC MI ANALYZE to account for randomness in multiple
imputations. Statistical testing for interactions of race with
each intervention (GM-CSF and exercise) for their effects on
outcomes was performed to compare the treatment effect in
black participants with the treatment effect in white partic-
ipants. Analyses for interactions were repeated using anal-
yses of covariance to adjust for differences in age, ABI, BMI,
*Data were imputed for parcipants who were lost to follow-up or who canceled the visit.
12-Week Follow-Up
Lost to follow-up (n=2)
Death (n=2)
Lost to follow-up (n=1)
Canceled visit (n=2)
Discontinued health 
education sessions (lost 
interest) (n=1)
Lost to follow-up (n=3) Lost to follow-up (n=4)
Canceled visit (n=1)
Analyzed (n=51)*
Excluded from analysis
(death) (n=2)
Analyzed (n=51)* Analyzed (n=52)* Analyzed (n=49)*
26-Week Follow-Up
Lost to follow-up (n=3)
Death (n=2)
Lost to follow-up (n=2)
Death (n=1)
Lost to follow-up (n=3) Lost to follow-up (n=5)
Discontinued health 
education sessions 
(moved) (n=1)
Analyzed (n=51)*
Excluded from analysis 
(death) (n=2)
Analyzed (n=50)
Excluded from analysis 
(death) (n=1)
Analyzed (n=52)* Analyzed (n=49)*
Figure 1. Continued.
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leg symptoms, and smoking across the 4 groups defined by
treatment and race, since these characteristics differed
between black and white participants and were considered
potential confounders. People who died were excluded from
analyses at time points that occurred after their deaths. The
analyses reported here were exploratory and statistical
significance was defined as P<0.05. Analyses were per-
formed using SAS software version 9.4 (Cary, NC).
Results
Of 827 potential participants who attended a baseline visit,
617 met 1 or more exclusion criteria and 210 were
randomized (Figure 1). Of these, 141 participants (67.1%)
were black and 64 (30.5%) were white. Five participants
(2.4%) who identified themselves as neither black nor white
were excluded.
Overall, 189/205 (92.2%) of participants had an ABI <0.90,
9 (4.4%) had an ABI of 0.90 to <1.0, and 7 (3.4%) had an ABI
≥1.0 at baseline. Among participants who were black, the
corresponding number and proportion of participants in each
category was 131 (92.9%), 6 (4.3%), and 4 (2.8%),
respectively. Among participants who were white, the corre-
sponding number and percent were 58 (90.6%), 3 (4.7%), and
3 (4.7%), respectively.
Among the 64 whites randomized, 61 (95.3%) completed 6-
week follow-up, 61 (95.3%) completed 12-week follow-up, and
61 (95.3%) completed 26-week follow-up. Among the 141
black participants who were randomized, 132 (93.6%) com-
pleted 6-week follow-up, 129 (91.5%) completed 12-week
follow-up, and 128 (90.8%) completed 26-week follow-up. The
number of participants missing data for each outcome is
shown by race in Table 1. There were no statistically
significant interactions of GM-CSF and exercise (P value for
statistical interaction at 6-week follow-up=0.65, P value for
interaction at 12-week follow-up=0.64, P value for statistical
interaction at 26-week follow-up=0.96).
Black participants were younger, had a lower BMI, and had
a higher prevalence of current cigarette smoking and a lower
prevalence of classic intermittent claudication symptoms,
compared with white participants (Table 2). Table 3 compares
black and white participants according to randomization to
GM-CSF versus placebo and according to randomization to
supervised exercise versus attention control.
Table 1. Missing Data for Each Outcome at Each Time Point by Race
Black Participants White Participants
Total (N=202)GM-CSF (N=69) Placebo (N=71) GM-CSF (N=32) Placebo (N=30)
Six-min walk*
6-wk 4 (5.8%) 5 (7.0%) 2 (6.3%) 2 (6.7%) 13 (6.4%)
12-wk 5 (7.2%) 9 (12.7%) 0 (0%) 1 (3.3%) 15 (7.4%)
26-wk 5 (7.2%) 9 (12.7%) 0 (0%) 1 (3.3%) 15 (7.4%)
Brachial artery flow-mediated dilation
Baseline 2 (2.9%) 2 (2.8%) 1 (3.1%) 2 (6.7%) 7 (3.5%)
6-wk 9 (13.0%) 6 (8.5%) 2 (6.3%) 4 (13.3%) 21 (10.4%)
12-wk 7 (10.1%) 11 (15.5%) 1 (3.1%) 3 (10.0%) 22 (10.9%)
26-wk 7 (10.1%) 9 (12.7%) 1 (3.1%) 5 (16.7%) 22 (10.9%)
Exercise (N=67)
Attention
Control (N=73) Exercise (N=36)
Attention
Control (N=26) Total (N=202)
Six-min walk*
6-wk 4 (6.0%) 5 (6.8%) 1 (2.8%) 3 (11.5%) 13 (6.4%)
12-wk 4 (6.0%) 10 (13.7%) 1 (2.8%) 0 (0%) 15 (7.4%)
26-wk 6 (9.0%) 8 (11.0%) 1 (2.8%) 0 (0%) 15 (7.4%)
Brachial artery flow-mediated dilation
Baseline 3 (4.5%) 1 (1.4%) 1 (2.8%) 2 (7.7%) 7 (3.5%)
6-wk 7 (10.4%) 8 (11.0%) 2 (5.6%) 4 (15.4%) 21 (10.4%)
12-wk 7 (10.4%) 11 (15.1%) 2 (5.6%) 2 (7.7%) 22 (10.9%)
26-wk 7 (10.4%) 9 (12.3%) 4 (11.1%) 2 (7.7%) 22 (10.9%)
GM-CSF indicates granulocyte-macrophage colony-stimulating factor.
*There were no missing data for 6-minute walk distance at baseline.
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Among participants randomized to GM-CSF, black partic-
ipants received 351 out of 420 possible injections (83.6%),
while white participants received 187 out of 204 possible
injections (91.7%) (P=0.37). Among participants randomized
to placebo, black participants received 393 out of 426
possible injections (92.3%) and white participants received
174 out of 180 possible placebo injections (96.7%) (P=0.83).
Among participants randomized to exercise, black partici-
pants attended 3111 out of a possible 4510 exercise sessions
(69.0%) and white participants attended 1891 out of a
possible 2543 exercise sessions (74.4%) (P=0.14). Among
participants randomized to attention control, black partici-
pants attended 1175 out of a possible 1550 sessions (75.8%)
and white participants attended 455 out of a possible 599
sessions (76.0%) (P=0.51).
Progenitor Cell Increases in Response to GM-CSF
Circulating progenitor cells significantly increased among
white and among black participants, respectively, at 2-week
follow-up (Table S1). There were no significant differences
in the magnitude of progenitor cell increases in blacks
versus whites who received GM-CSF at 2-week follow-up
(Table S1).
Effects of GM-CSF Versus Placebo on 6-Minute
Walk
Among white participants, GM-CSF increased the 6-minute
walk by +12.9 m (95% CI: 10.8, +36.5, P=0.29) at 6-week
follow-up, +22.0 m (95% CI:4.5, +48.5, P=0.103) at 12-week
follow-up, and +44.4 m (95% CI: +6.9, +82.0, P=0.020) at
26-week follow-up, compared with placebo (Table 4 and
Figure 2A). Among black participants, GM-CSF did not increase
the 6-minute walk (Table 4 and Figure 2A). There was a
statistically significant interaction for race on the effect of GM-
CSF on change in 6-minute walk distance at 26-week follow-
up (P=0.018) and a nearly statistically significant effect at 12-
week follow-up (P=0.076). Results did not substantially
change when analyses were repeated, adjusting for baseline
differences in age, ABI, BMI, leg symptoms, and smoking
between blacks and whites (interaction term at 12-week
follow-up: P=0.078, interaction term at 26-week follow-up:
P=0.028). When results were repeated among the 189
participants with ABI <0.90, results were similar; however, at
12-week follow-up, GM-CSF had a statistically significant
effect on improvement in 6-minute walk among white
participants (+29.0 m, 95% CI: +1.2, +56.8, P=0.041). The
statistical significance of the interaction term for race on the
effect of GM-CSF on change in 6-minute walk was P=0.012 at
12-week follow-up and P=0.008 at 26-week follow-up among
participants with ABI <0.90.
Effects of Supervised Treadmill Exercise Versus
Attention Control on 6-Minute Walk
Among white participants, supervised treadmill exercise
increased the 6-minute walk distance by +19.5 m (95% CI:
4.4, +43.5, P=0.11) at 6-week follow-up, by +26.2 m
(95% CI: 0.3, +52.7, P=0.053) at 12-week follow-up, and
by +44.5 m (+6.5, +82.5, P=0.022) at 26-week follow-up,
compared with control (Table 5 and Figure 2B). Among
black participants, supervised treadmill exercise increased
6-minute walk distance by +13.4 m (95% CI: 4.4, +31.2,
P=0.14) at 6-week follow-up, by +37.8 m (95% CI=+14.7,
+61.0, P=0.001) at 12-week follow-up, and by +31.9 m
(95% CI: +9.7, +54.1, P=0.005) at 26-week follow-up,
compared with control (Table 5 and Figure 2B). There were
no statistically significant interactions of race on the effect
of supervised exercise on change in 6-minute walk
performance. Results did not substantially change when
analyses were repeated, adjusting for racial differences in
age, ABI, BMI, leg symptoms, and smoking. Findings were
Table 2. Characteristics of Black Versus White Participants
in the PROPEL Trial
Characteristic Black (N=141) White (N=64) P Value
Age, y 65.8 (7.8) 69.4 (9.6) 0.004
Men N=82 (58.2%) N=43 (67.2%) 0.22
ABI 0.68 (0.18) 0.73 (0.21) 0.070
BMI, kg/m2 29.8 (6.3) 32.2 (6.7) 0.017
Current cigarette
smoking
N=57 (40.4%) N=13 (20.3%) 0.005
Former cigarette
smoking
N=75 (53.2%) N=38 (59.4%) 0.41
Hypertension N=118 (83.7%) N=53 (82.8%) 0.88
Diabetes mellitus N=48 (34.0%) N=29 (45.3%) 0.12
Angina N=31 (22.0%) N=11 (17.2%) 0.43
Heart failure N=19 (13.5%) N=8 (12.5%) 0.85
Myocardial infarction N=29 (20.6%) N=16 (25.0%) 0.48
Baseline 6-min
walk, m
332.6 (98.3) 349.9 (102.3) 0.25
Intermittent
claudication
N=37 (26.2%) N=26 (40.6%) 0.039
Baseline progenitor cell concentration (%)
CD34+CD45lo 0.026 (0.016) 0.028 (0.014) 0.38
CD34+CD45loCD133+ 0.016 (0.010) 0.017 (0.010) 0.44
CD34+CD45loCD31+ 0.023 (0.015) 0.025 (0.014) 0.32
CD34+CD45loCD31+
CD133+
0.017 (0.013) 0.018 (0.010) 0.59
ABI indicates ankle-brachial index; BMI, body mass index; PROPEL, Progenitor Cell
Release Plus Exercise to Improve Functional Performance in PAD.
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not substantially changed when black and white partici-
pants were categorized according to presence versus
absence of diabetes mellitus (Tables S2 and S3).
Figure S1 shows the effects of each of the 4 study groups
(GM-CSF+exercise, GM-CSF+control, placebo+exercise, and
placebo+control) on change in 6-minute walk distance at each
follow-up time point by participant race.
Brachial Artery FMD
Among white participants, GM-CSF significantly improved
brachial artery FMD at 6-week follow-up, compared with
placebo (+1.96%, 95% CI: +0.51, +3.42, P=0.008), but there
were no effects of GM-CSF on brachial artery FMD at 12- or
26-week follow-up (Table S2). Among black participants, there
was no effect of GM-CSF on brachial artery FMD at any time
point (Table S4). Exercise did not increase brachial artery FMD
at any time point among blacks or whites (Table S5).
Serious Adverse Events
Twenty-two of 70 (31.4%) black participants who received
GM-CSF had 1 or more serious adverse events, compared
with 13 of 71 (18.3%) black participants who received placebo
Table 3. Characteristics of Participants by Race and Randomization Assignment
Characteristic
Black Participants White Participants
GM-CSF (N=70) Placebo (N=71) GM-CSF (N=34) Placebo (N=30)
Age, y 66.3 (7.8) 65.3 (7.9) 69.0 (9.7) 70.0 (9.5)
ABI, mean (SD) 0.70 (0.19) 0.66 (0.16) 0.71 (0.18) 0.75 (0.24)
Women, N (%) 27 (38.6) 32 (45.1) 11 (32.4) 10 (33.3)
BMI, kg/m2 29.8 (6.8) 29.9 (5.8) 31.0 (6.5) 33.5 (6.8)
Diabetes mellitus, N (%) 24 (34.3) 24 (33.8) 15 (44.1) 14 (46.7)
Angina history, N (%) 20 (28.6) 11 (15.5) 7 (20.6) 4 (13.3)
Myocardial infarction, N (%) 18 (25.7) 11 (15.5) 12 (35.3) 4 (13.3)
Heart failure, N (%) 10 (14.3) 9 (12.7) 5 (14.7) 3 (10.0)
Pulmonary disease 7 (10.0) 11 (15.5) 7 (20.6) 1 (3.3)
Intermittent claudication 16 (22.9) 21 (29.6) 14 (41.2) 12 (40.0)
Atypical exertional leg symptoms 50 (71.4) 49 (69.0) 18 (52.9) 16 (53.3)
Six-min walk, m 336.0 (100.3) 329.2 (96.9) 338.4 (115.7) 362.9 (84.8)
Randomized to supervised treadmill exercise 35 (50.0) 33 (46.5) 18 (52.9) 19 (63.3)
Characteristic
Black Participants White Participants
Exercise (N=68)
Attention Control
(N=73)
Exercise
(N=37)
Attention Control
(N=27)
Age, mean (SD) (y) 65.5 (7.6) 66.0 (8.0) 69.7 (10.8) 69.1 (7.6)
ABI, mean (SD) 0.68 (0.19) 0.68 (0.17) 0.73 (0.21) 0.73 (0.21)
Women, N (%) 30 (44.1) 29 (39.7) 13 (35.1) 8 (29.6)
BMI, kg/m2 30.1 (6.2) 29.6 (6.4) 32.2 (6.2) 32.2 (7.4)
Diabetes mellitus, N (%) 25 (36.8) 23 (31.5) 13 (35.1) 16 (59.3)
Angina history, N (%) 14 (20.6) 17 (23.3) 8 (21.6) 3 (11.1)
Myocardial infarction, N (%) 12 (17.7) 17 (23.3) 9 (24.3) 7 (25.9)
Heart failure, N (%) 7 (10.3) 12 (16.4) 3 (8.1) 5 (18.5)
Pulmonary disease, N (%) 7 (10.3) 11 (15.1) 5 (13.5) 3 (11.1)
Intermittent claudication, N (%) 22 (32.4) 15 (20.6) 15 (40.5) 11 (40.7)
Atypical exertional leg symptoms, N (%) 44 (64.7) 54 (74.0) 18 (48.6) 16 (59.3)
Six-min walk, m 330.1 (105.0) 334.8 (92.4) 353.5 (97.3) 344.9 (110.6)
Randomized to supervised treadmill exercise, N (%) 35 (51.5) 35 (47.9) 18 (48.6) 16 (59.3)
ABI indicates ankle-brachial index; BMI, body mass index; GM-CSF, granulocyte-macrophage colony-stimulating factor.
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(P=0.071). Eight of 34 (23.5%) white participants who
received GM-CSF group had 1 or more serious adverse
events, compared with 8 of 30 (26.7%) white participants who
received placebo (P=0.77). Seventeen of 68 (25.0%) black
participants in the exercise group reported at least 1 serious
adverse event, compared with 18 of 73 (24.7%) black
participants in the health education group (N=0.96). Ten of
37 (27.0%) white participants reported at least 1 serious
adverse event in the exercise group, compared with 6 of 27
(22.2%) in the health education group (N=0.66). Three deaths
occurred during the study: 1 among black participants and 2
among white participants. No deaths were considered to be
related to study interventions.
Discussion
In exploratory analyses of the PROPEL Trial, GM-CSF had a
significantly greater effect on improving 6-minute walk
Table 4. Effects of GM-CSF on Changes in 6-Minute Walk Distance Over Time Among Black and White Participants (Data Shown
Are in Meters)
Black White
GM-CSF (N=69) Placebo (N=71) GM-CSF (N=32) Placebo (N=30)
Baseline 333 (98) 329 (97) 346 (115) 363 (85)
6-wk follow-up 344 (94) 338 (93) 360 (110) 364 (84)
12-wk follow-up 334 (99) 344 (96) 367 (105) 362 (96)
26-wk follow-up 346 (102) 347 (90) 371 (115) 344 (113)
Within-group change at 6-wk follow-up +11.1 (1.3, +23.6) +8.9 (3.7, +21.4) +14.1 (2.3, +30.6) +1.2 (15.7, +18.2)
Between-group change at 6-wk
follow-up (mean difference in change, 95% CI)
+2.3 (15.3, +19.8)
P=0.80
+12.9 (10.8, +36.5)
P=0.29
Within-group change at 12-wk follow-up +0.8 (15.9, +17.6) +14.4 (2.2, +31.1) +20.9 (+2.9, +38.9) 1.1 (20.0, +17.9)
Between-group change at 12-wk follow-up 13.6 (37.4, +10.3)
P=0.26
+22.0 (4.5, +48.5)
P=0.103
Within-group change at 26-wk follow-up +12.4 (3.3, +28.2) +17.4 (+1.2, +33.6) +25.4 (0.3, +51.1) 19.1 (45.8, +7.6)
Between-group change at 26-wk follow-up 5.0 (27.5, +17.5)
P=0.66
+44.4 (+6.9, +82.0)
P=0.020
GM-CSF indicates granulocyte-macrophage colony-stimulating factor.
Table 5. Effects of Exercise on Changes in 6-Minute Walk Distance Over Time Among Black and White Participants (Data Shown
Are in Meters)
Black White
Exercise (N=67) Attention Control (N=73) Exercise (N=36) Attention Control (N=26)
Baseline 327 (103) 335 (92) 356 (97) 351 (108)
6-wk follow-up 344 (98) 338 (90) 372 (90) 348 (107)
12-wk follow-up 355 (97) 324 (96) 378 (89) 346 (112)
26-wk follow-up 359 (96) 335 (96) 379 (101) 329 (126)
Within-group change: 6-wk follow-up +17.0 (+4.2, +29.8) +3.6 (8.7, +15.8) +16.1 (+0.9, +31.2) 3.5 (21.9, +14.9)
Between-group change: 6-wk follow-up +13.4 (4.4, +31.2)
P=0.14
+19.5 (4.4, +43.5)
P=0.11
Within-group change: 12-wk follow-up +27.5 (+11.1, +43.8) 10.4 (26.4, +5.7) +21.3 (+4.1, +38.4) 4.9 (24.7, +14.9)
Between-group change: 12-wk +37.8 (+14.7, +61.0)
P=0.001
+26.2 (0.3, +52.7)
P=0.053
Change between baseline and 26-wk follow-up +31.6 (+16.2, +47.0) 0.3 (16.2, +15.5) +22.5 (1.9, +46.9) 22.0 (50.5, +6.6)
Between group change: 26-wk +31.9 (+9.7, +54.1)
P=0.005
+44.5 (+6.5, +82.5)
P=0.022
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distance among white participants with PAD, compared with
black participants with PAD. Among white participants, GM-
CSF improved the 6-minute walk distance by 10.9 m at
6-week follow-up, 22.2 m at 12-week follow-up, and 45.3 m
at 26-week follow-up, compared with placebo. This magnitude
of effect was consistent with a clinically important difference
at 12- and at 26-week follow-up.25 However, GM-CSF had no
effect on change in 6-minute walk distance among partici-
pants who were black. A statistically significant interaction
was observed for white versus black race for the effect of
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Figure 2. The effect of GM-CSF on change in 6-minute walk distance among black and white participants with PAD. A, Among white
participants with peripheral artery disease (PAD), P=0.074 for the difference in overall change in 6-minute walk distance between (GMCSF) and
placebo. Among black participants with PAD, P=0.70 for difference in overall change in 6-minute walk distance between GMCSF and placebo. B,
The effect of exercise on change in 6-minute walk distance among black and white participants with PAD. Among white participants with PAD,
P=0.034 for difference in overall change in 6-minute walk distance between exercise and control. Among black participants with PAD, P=0.006
for difference in overall change in 6-minute walk distance between exercise and control. GM-CSF indicates granulocyte-macrophage colony-
stimulating factor; PAD, peripheral artery disease.
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GM-CSF on change in 6-minute walk distance at 26-week
follow-up. In contrast, supervised treadmill exercise improved
the 6-minute walk in both black and white participants, and
there was no significant interaction for race on the effect of
supervised treadmill exercise on 6-minute walk.
The reason for the observed racial difference in response
to GM-CSF is unclear. Since GM-CSF was administered
subcutaneously by study staff, and rates of attendance at GM-
CSF injection visits were similar between blacks and whites,
adherence to GM-CSF should not explain the observed racial
differences. In addition, there was no racial difference in the
effect of GM-CSF on increases in circulating progenitor cells,
suggesting that racial differences in the magnitude of increase
in circulating progenitor cell increases do not explain the
racial differences reported here. GM-CSF significantly
increased brachial artery FMD at 6-week follow-up in white
but not in black participants, suggesting a potential mecha-
nism for racial differences. However, this difference was not
observed at 12- or 26-week follow-up.
There are several potential explanations for results
reported here of racial differences in responsiveness to GM-
CSF. First, prior study showed lower quantities of circulating
progenitor cells in blacks compared with whites.31,32 In 1
study of 1747 people (including 457 [26%] black participants),
black participants had significantly fewer circulating progen-
itor cells than whites and these findings were also observed in
a second independent cohort.31 Second, among 91 people
presenting with an acute myocardial infarction, black patients
had significantly lower circulating progenitor cell abundance
compared with white patients (ie, 1316 versus 2231
CD34+ cells/mL, P=0.01).31 Third, in a study of umbilical
cord blood, blacks had significantly lower umbilical blood
progenitor cell counts compared with whites.32 Fourth, the
Framingham Heart Study demonstrated a heritable compo-
nent of circulating CD34+ progenitor cells.33,34 Additional
evidence demonstrated that blacks had poorer microvascular
endothelial function compared with whites.35 Although the
PROPEL trial did not demonstrate racial differences in
progenitor cell increases in response to GM-CSF, it is possible
that findings reported here can be explained by racial
differences in responsiveness to increased progenitor cells.
It is also possible that there were racial differences in specific
progenitor cells or responsiveness to progenitor cells that
were not measured in the PROPEL Trial.
It is possible that racial differences in atherosclerosis
location or severitymight explain the racial differences reported
here. Previous study demonstrated more severe infragenicular
atherosclerosis in black patients compared with white
patients.3 Among patients presenting with critical limb
ischemia, whites were more likely to present with isolated
aortoiliac disease than blacks36 and 5 years after infrainguinal
bypass grafting, blacks had poorer graft patency than whites.37
Prior evidence regarding the effects of GM-CSF in patients
with PAD was mixed.10,16,38,39 The PROPEL trial included 210
participants, was the largest trial to study GM-CSF in people
with PAD, and showed no overall benefit of GM-CSF on
walking distance in PAD.16 Poole et al randomized 159
participants with PAD and intermittent claudication to GM-
CSF versus placebo.38 There was no significant improvement
in the primary outcome, 12-week change in maximal treadmill
walking time, as compared with placebo (mean differ-
ence=53 s, P=0.08) and only 2 of 9 secondary outcomes—
change in the Walking Impairment Questionnaire distance
score and change in the 36-item short-form health survey
physical functioning score—were significantly better in the
GM-CSF group compared with placebo at 12-week follow-up.
In this prior study, 78 (49.1%) PAD participants were white
and 79 (49.7%) were black. A third study of 45 participants
with PAD reported a significant benefit of GM-CSF on
treadmill walking performance, but participant race was not
reported.10 A fourth study of 40 participants with PAD
conducted in Europe demonstrated no effect of GM-CSF on
treadmill walking distance.39
This study has limitations. First, results reported here were
not prespecified, are considered exploratory, and require
confirmation. Second, statistical power for the PROPEL trial
was not calculated separately for black and white partici-
pants. Third, it is possible that there were racial differences in
improvements of other types of endothelial progenitor cells,
responsiveness to endothelial progenitor cells, or other
unmeasured factors that explain these findings but were not
measured in PROPEL.
Conclusion
GM-CSF significantly improved the 6-minute walk at 26-week
follow-up among people with PAD who were white, but had no
effect on people with PAD who were black. Further study is
needed to confirm the racial differences reported here in
response to GM-CSF among people with PAD.
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     Supplemental Material 
Table S1. Two-week change in progenitor cell abundance by receipt of GM-CSF vs. 
placebo among blacks and whites with peripheral artery disease. 
 
Race  
No. 
Mean (SD) Mean (95% CI) P 
interact Baseline  2-week follow-up Within-group Change Difference in Changes  P value  
CD34_CD45lo 
Black GM-CSF 56 0.026 (0.014) 0.050 (0.045) +0.025 (+0.016, +0.033) +0.022 (+0.010, +0.034) .0003 0.8277 
Placebo 62 0.026 (0.017) 0.028 (0.020) +0.003 (-0.005, +0.011) Reference - 
White GM-CSF 28 0.030 (0.014) 0.055 (0.052) +0.025 (+0.013, +0.038) +0.024 (+0.007, +0.042) .0076 
Placebo 28 0.027 (0.011) 0.028 (0.014) +0.001 (-0.011, +0.014) Reference - 
CD34_CD45loCD133_ 
Black GM-CSF 56 0.016 (0.009) 0.032 (0.031) +0.016 (+0.010, +0.022) +0.014 (+0.005, +0.022) .0015 0.7257 
Placebo 62 0.016 (0.011) 0.019 (0.014) +0.003 (-0.003, +0.008) Reference - 
White GM-CSF 28 0.018 (0.010) 0.036 (0.034) +0.018 (+0.010, +0.026) +0.016 (+0.005, +0.028) .0069 
Placebo 28 0.017 (0.009) 0.019 (0.011) +0.002 (-0.006, +0.010) Reference - 
CD34_CD45lo_CD31_ 
Black GM-CSF 43 0.022 (0.013) 0.041 (0.032) +0.019 (+0.011, +0.026) +0.017 (+0.007, +0.027) .0009 0.2429 
Placebo 47 0.023 (0.016) 0.024 (0.020) +0.001 (-0.005, +0.008) Reference - 
White GM-CSF 19 0.031 (0.014) 0.063 (0.053) +0.032 (+0.016, +0.048) +0.030 (+0.007, +0.053) 0.0131 
Placebo 18 0.022 (0.011) 0.025 (0.014) +0.003 (-0.014, +0.019) Reference - 
CD34_CD45lo_CD31_CD133_ 
Black GM-CSF 43 0.015 (0.009) 0.029 (0.023) +0.014 (+0.008, +0.019) +0.013 (+0.005, +0.021) .0009 0.3032 
Placebo 47 0.017 (0.013) 0.017 (0.014) +0.001 (-0.005, +0.006) Reference - 
White GM-CSF 19 0.021 (0.009) 0.044 (0.036) +0.024 (+0.013, +0.035) +0.021 (+0.005, +0.037) 0.0109 
Placebo 18 0.016 (0.010) 0.019 (0.012) +0.003 (-0.009, +0.014) Reference - 
Table S2. Effects of GM-CSF on changes in six-minute walk distance over time among black and 
white participants who do not have diabetes (data are shown in meters). 
 Black participants without 
diabetes 
White participants without 
diabetes 
 GM-CSF 
N=45 
Placebo 
N=47 
GM-CSF 
N=18 
Placebo 
N=16 
Baseline 351 (91) 342 (98) 337 (141) 367 (74) 
6-week follow-up 365 (88) 352 (85) 355 (127) 371 (75) 
12-week follow-up 349 (96) 356 (90) 377 (119) 366 (86) 
26-week follow-up 362 (97) 355 (90) 376 (125) 342 (126) 
Within group change at 6-
week follow-up 
+14.1  
 (+0.7, +27.6) 
+9.6  
 (-3.8, +22.9) 
+18.0 
(-6.1, +42.1) 
+4.1 
(-21.5, +29.7) 
Between group change at 6-
week follow-up (mean 
difference in change, 95% CI) 
+4.6  
(-14.4, +23.6) 
P=0.64 
+13.9 
(-22.4, +50.1) 
P=0.45 
Interaction at 6-week follow-
up 
-9.3 (-46.6, +28.0) 
P=0.62 
Within group change at 12-
week follow-up 
-1.5  
 (-19.5, +16.5) 
+14.0  
 (-4.0, +31.9) 
+39.6 
(+14.1, +65.2) 
-0.4 
(-27.5, +26.7) 
Between group change at 12-
week follow-up 
-15.4  
(-41.2, +10.3) 
P=0.24 
+40.0 
(+1.6, +78.5) 
P=0.041 
Interaction at 12-week follow-
up 
-55.5 (-101.9, -9.0) 
P=0.019 
Within group change at 26- 
week follow-up 
+11.4  
 (-5.5, +28.3) 
+13.3  
 (-3.6, +30.2) 
+38.4 
(-2.1, +78.9) 
-24.5 
(-67.5, +18.4) 
Between group change at 26-
week follow-up 
-1.9  
(-26.5, +22.7) 
P=0.88 
+62.9 
(+2.1, +123.8) 
P=0.043 
Interaction at 26-week follow-
up 
-64.8 (-116.6, -13.0) 
P=0.014 
 
  
Table S3. Effects of GM-CSF on changes in six-minute walk distance over time among black 
and white participants with diabetes (data are shown in meters). 
 Black participants with diabetes White participants with diabetes 
 GM-CSF 
N=24 
Placebo 
N=24 
GM-CSF 
N=14 
Placebo 
N=14 
Baseline 300 (103) 304 (91) 357 (72) 359 (98) 
6-week follow-up 306 (94) 312 (105) 366 (87) 357 (95) 
12-week follow-up 305 (101) 319 (106) 354 (86) 357 (109) 
26-week follow-up 314 (108) 330 (90) 365 (105) 346 (101) 
Within group change at 6-week 
follow-up 
+5.5  
 (-20.5, +31.5) 
+7.5  
 (-19.1, +34.1) 
+9.1  
 (-13.2, +31.3) 
-2.1  
 (-24.0, +19.8) 
Between group change at 6-week 
follow-up (mean difference in 
change, 95% CI) 
-2.0  
(-39.5, +35.6) 
P=0.92 
+11.2  
(-20.3, +42.7) 
P=0.49 
Interaction at 6-week follow-up -13.1 (-66.3, +40.0) P=0.63 
Within group change at 12-week 
follow-up 
+5.2  
 (-29.5, +39.9) 
+15.3  
 (-20.2, +50.8) 
-3.1  
 (-26.0, +19.8) 
-1.9  
 (-26.1, +22.3) 
Between group change at 12-week 
follow-up 
-10.1  
(-60.4, +40.1) 
P=0.69 
-1.2  
(-35.8, +33.3) 
P=0.94 
Interaction at 12-week follow-up -8.9 (-78.4, +60.6) P=0.80 
Within group change at 26- week 
follow-up 
+14.3  
 (-18.6, +47.3) 
+25.5  
 (-9.0, +60.0) 
+8.6  
 (-19.7, +36.9) 
-12.9  
 (-41.9, +16.2) 
Between group change at 26-week 
follow-up 
-11.2  
(-59.5, +37.1) 
P=0.65 
+21.4  
(-20.8, +63.6) 
P=0.32 
Interaction at 26-week follow-up -32.6 (-101.5, +36.2) P=0.35 
 
Table S4. Effects of GM-CSF on brachial artery flow-mediated dilation according to black vs. white 
race*. 
 Black White 
 GM-CSF 
N=69 
Placebo 
N=71 
GM-CSF 
N=32 
Placebo 
N=30 
Baseline 5.8% (3.7, 7.6) 4.7% (2.9, 6.3) 4.8% (2.9, 5.6) 6.8% (4.2, 9.5) 
6-week follow-up 5.5% (2.8, 8.7) 4.3% (2.8, 7.5) 5.1% (3.6, 7.2) 5.9% (3.6, 8.7) 
12-week follow-up 5.3% (3.2, 8.0) 3.9% (2.2, 6.4) 4.2% (2.6, 6.4) 6.9% (3.7, 9.8) 
26-week follow-up 5.8% (3.7, 7.8) 4.0% (2.5, 7.2) 3.9% (2.2, 6.1) 5.3% (2.3, 7.3) 
Within group change at 6-
week follow-up 
+0.10%  
(-1.42, +1.88) 
-0.07%  
(-1.33, +1.91) 
+0.65%  
(-0.89, +1.96) 
-1.00% 
(-3.26, +1.85) 
Between group change at 6-
week follow-up 
-0.07% (-0.92, +0.79) 
P=0.88 
+1.96% (+0.51, +3.42) 
P=0.008 
Interaction at 6-week follow-
up 
-2.03% (-3.72, -0.34) 
P=0.019 
Within group change at 12-
week follow-up 
+0.10% 
(-1.77, +1.18) 
-0.17%  
(-1.73, +2.04) 
-1.09%  
(-2.46, +1.81) 
-0.18%  
(-1.63, +1.40) 
Between group change at 12-
week follow-up 
-0.03% (-0.99, +0.93) 
P=0.95 
-0.24% (-1.78, +1.29) 
P=0.76 
Interaction at 12-week 
follow-up 
+0.21% (-1.60, +2.02) 
P=0.82 
Within group change at 26- 
week follow-up 
+0.16% 
(-1.57, +1.82) 
-0.08% 
(-2.04, +1.65) 
-0.73%  
(-1.71, +0.08) 
-1.37%  
(-4.16, -0.01) 
Between group change at 26-
week follow-up 
+0.22% (-0.73, +1.18) 
P=0.65 
+0.75% (-0.67, +2.16) 
P=0.30 
Interaction at 26-week 
follow-up 
-0.53% (-2.23, +1.18) 
P=0.54 
*Median (Interquartile range) is shown for the outcome at each time point, as well as for the 
within-group change. Estimate (95% CI).  P values for between-group changes are from the 
combined results for Hodges-Lehmann Estimation. Data were imputed for individuals who did 
not die but missed the outcome measure at each visit.  
Table S5. Effects of exercise on brachial artery flow-mediated dilation according to black vs. white 
race . 
 Black White 
 Exercise 
N=67 
Attention 
Control 
N=73 
Exercise 
N=36 
Attention 
Control 
N=26 
Baseline 4.9% (2.9, 7.4) 5.5% (3.8, 7.2) 5.0% (2.9, 9.5) 5.3% (3.5, 7.3) 
6-week follow-up 4.8% (2.4, 7.0) 5.5% (3.3, 9.0) 6.3% (4.1, 8.7) 5.1% (3.0, 6.6) 
12-week follow-up 4.4% (2.3, 6.4) 5.3% (3.0, 8.2) 4.7% (3.2, 8.7) 6.0% (3.4, 8.3) 
26-week follow-up 5.2% (2.5, 7.6) 5.0% (3.3, 7.8) 4.8% (2.2, 7.2) 3.8% (2.3, 5.5) 
Within group change: 6-week 
follow-up 
-0.20%  
(-1.45, +1.91) 
+0.28%  
(-1.26, +1.89) 
+0.25%  
(-1.72, +2.39) 
+0.15%  
(-1.89, +0.87) 
Between group change:  6-week 
follow-up 
-0.36% (-1.30, +0.57) 
P=0.44 
+0.88% (-0.73, +2.49) 
P=0.28 
Interaction at 6-week follow-up -1.24% (-3.10, +0.62) 
P=0.19 
Within-group change: 12-week 
follow-up 
-0.03%  
(-1.90, +1.24) 
-0.39%  
(-1.58, +1.80) 
-0.45%  
(-2.50, +1.40) 
-0.44%  
(-1.49, +1.64) 
Between group change: 12 week -0.16% (-1.12, +0.81) 
P=0.75 
-0.48% (-1.98, +1.02) 
P=0.53 
Interaction at 12-week follow-up +0.32% (-1.46, +2.10) 
P=0.73 
Change between baseline and 26-
week follow-up 
+0.33%  
(-1.48, +2.16) 
-0.27%  
(-2.04, +1.49) 
-0.73%  
(-1.95, +0.28) 
-1.13%  
(-3.69, -0.50) 
Between group change: 26 week +0.63% (-0.32, +1.57) 
P=0.19 
+0.47% (-0.66, +1.59) 
P=0.42 
Interaction at 26-week follow-up +0.16% (-1.31, +1.63) 
P=0.83 
*Median (interquartile range) is shown for the outcome at each time point, as well as for the 
within-group change. Estimate (95% CI).  P values for between-group changes are from the 
combined results for Hodges-Lehmann Estimation. Data were imputed for individuals who did 
not die but missed the outcome measure at each visit.  
  
 
 
 
Figure S1. Changes in six minute walk distance by group assignment among black and white participants in the PROPEL 
Trial. 
